About Ankyrin repeat domain-containing protein 1
Ankyrin repeat domain-containing protein 1 (ANKRD1) is a protein
from Homo sapiens identified by UniProt accession
Q15327, 319 residues long.
MolForge cross-references it against 0 known binders and
159 disease associations.
Target properties
| Protein name | Ankyrin repeat domain-containing protein 1 |
| UniProt accession | Q15327 |
| Gene | ANKRD1 |
| Organism | Homo sapiens |
| Length | 319 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (159)
Diseases linked to this target (Open Targets).
- familial isolated dilated cardiomyopathy · score 0.37
- electrocardiography · score 0.26
- refractive error measurement · score 0.26
- autosomal dominant dilated cardiomyopathy · score 0.23
- left atrial volume measurement · score 0.23
- ankrd1-related dilated cardiomyopathy · score 0.19
- Abnormality of the cardiovascular system · score 0.19
- Abnormality of refraction · score 0.19
- dilated cardiomyopathy · score 0.19
- cardiomyopathy · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15327-F1 | alphafold | PREDICTED | 82.78 | — |
Amino-acid sequence (319 residues)
MMVLKVEELV TGKKNGNGEA GEFLPEDFRD GEYEAAVTLE KQEDLKTLLA HPVTLGEQQW KSEKQREAEL KKKKLEQRSK LENLEDLEII IQLKKRKKYR KTKVPVVKEP EPEIITEPVD VPTFLKAALE NKLPVVEKFL SDKNNPDVCD EYKRTALHRA CLEGHLAIVE KLMEAGAQIE FRDMLESTAI HWASRGGNLD VLKLLLNKGA KISARDKLLS TALHVAVRTG HYECAEHLIA CEADLNAKDR EGDTPLHDAV RLNRYKMIRL LIMYGADLNI KNCAGKTPMD LVLHWQNGTK AIFDSLRENS YKTSRIATF
Explore Ankyrin repeat domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets